Platelet pheresis — the targeted collection of platelets from a single donor using an apheresis machine — has become the backbone of modern transfusion support for patients with severe thrombocytopenia, active bleeding, and hematologic malignancies. Unlike pooled random-donor platelets derived from whole blood, a single apheresis collection yields roughly 3–6 × 10¹¹ platelets (the equivalent of 4–6 whole blood units), reduces donor exposure, and carries a lower risk of alloimmunization and transfusion-transmitted infection.
If you’re a clinician weighing apheresis vs. whole-blood-derived platelets, a trainee studying for boards, or a patient trying to understand why your oncologist ordered “single-donor platelets,” this article covers the clinical implications and the most meaningful recent advances in platelet pheresis — with real numbers, not just generalizations.
How Platelet Pheresis Actually Works
During apheresis, whole blood is drawn from the donor’s antecubital vein into a centrifuge-based separator. The machine isolates the platelet-rich layer (the “buffy coat” zone), collects it into a storage bag with anticoagulant (typically ACD-A), and returns red cells and plasma to the donor through the same or a second venous access.
A typical session takes 60–90 minutes. Donors need a pre-procedure platelet count ≥150 × 10⁹/L, and most centers cap donation frequency at 24 times per year (per AABB standards) to prevent donor thrombocytopenia.
Apheresis vs. Whole-Blood-Derived Platelets: Head-to-Head
| Parameter | Apheresis Platelets (Single Donor) | Whole-Blood-Derived Platelets (Pooled) |
|---|---|---|
| Platelet yield per dose | 3.0–6.0 × 10¹¹ | ~3.0 × 10¹¹ (pooled from 4–6 donors) |
| Donor exposures per transfusion | 1 | 4–6 |
| HLA alloimmunization risk | Lower | Higher |
| Bacterial contamination risk | Lower (single collection system) | Higher (multiple pooling steps) |
| Cost per therapeutic dose | $500–$600 (U.S. average) | $400–$500 |
| Shelf life (22°C with agitation) | 5 days | 5 days |
| Compatible with pathogen reduction? | Yes (Intercept, Mirasol) | Yes, but more complex logistically |
The bottom line: apheresis platelets cost slightly more but meaningfully reduce donor exposure — a critical advantage for patients who will need repeated transfusions (e.g., leukemia induction chemotherapy, stem cell transplant recipients).
Key Clinical Indications for Platelet Pheresis Products
- Hematologic malignancies: Patients undergoing chemotherapy or hematopoietic stem cell transplant routinely receive prophylactic platelet transfusions when counts drop below 10 × 10⁹/L (or <20 × 10⁹/L with fever or active infection).
- Massive transfusion protocols: Trauma and surgical hemorrhage where dilutional thrombocytopenia develops.
- Immune thrombocytopenic purpura (ITP): Platelet transfusion is generally reserved for life-threatening bleeding since transfused platelets are rapidly consumed. Apheresis products are preferred when transfusion is unavoidable.
- Aplastic anemia and bone marrow failure syndromes.
- Neonatal alloimmune thrombocytopenia (NAIT): HPA-matched apheresis platelets can be lifesaving.
- Platelet refractoriness: HLA-matched apheresis donors are the primary solution for patients who no longer respond to random-donor platelets (defined as a corrected count increment <5,000 at 1 hour on two consecutive transfusions).
7 Advances Reshaping Platelet Pheresis
1. Pathogen Reduction Technology (PRT)
The Intercept Blood System (amotosalen + UVA) and Mirasol (riboflavin + UV) inactivate bacteria, viruses, and parasites in collected platelets. The FDA approved Intercept-treated platelets with a 5-day shelf life without requiring bacterial culture, streamlining inventory management. A 2023 Lancet Haematology meta-analysis showed PRT reduced septic transfusion reactions by approximately 75%.
2. Cold-Stored Platelets
Refrigerating platelets at 1–6°C (instead of room temperature) improves hemostatic function and extends usable shelf life. The U.S. Department of Defense has championed cold-stored apheresis platelets for battlefield trauma. Early clinical data show superior clot strength (by thromboelastography) compared to room-temperature-stored products.
3. Extended Storage with Platelet Additive Solutions (PAS)
Replacing 60–70% of plasma with PAS (e.g., PAS-C, InterSol) reduces allergic and febrile transfusion reactions by lowering residual plasma protein load. Studies show a 40–50% reduction in allergic reactions with PAS-based storage.
4. Automated Double- and Triple-Dose Collections
Modern apheresis platforms (Trima Accel, Amicus) can collect 2–3 therapeutic doses from a single high-count donor in one sitting, dramatically improving blood bank efficiency.
5. HLA-Matched and Crossmatched Donor Registries
Large donor registries now enable rapid HLA-A/B matching for refractory patients. Some centers report corrected count increment success rates above 60% with prospectively HLA-matched apheresis products, compared to <20% with random units.
6. Point-of-Care Platelet Function Testing
Devices like the Multiplate analyzer and TEG 6s allow clinicians to assess platelet function in the transfused product and in the recipient — guiding real-time transfusion decisions rather than relying solely on platelet counts.
7. Artificial and Synthetic Platelet Substitutes
Still in preclinical stages, synthetic platelet mimetics (e.g., fibrin-targeted nanoparticles) aim to supplement or replace donor-dependent platelet transfusion. Early animal models show promising hemostatic efficacy, though clinical trials are likely 5–10 years away.
Donor Factors That Affect Platelet Yield
Not all donors produce equal apheresis yields. Key variables include:
- Pre-donation platelet count: Donors with counts >250 × 10⁹/L consistently yield double doses.
- Hydration status: Dehydrated donors have higher hematocrit levels, which slow separation efficiency.
- NSAID use: Aspirin or ibuprofen within 48 hours irreversibly inhibits cyclooxygenase, producing functionally impaired platelets. Most centers defer these donors.
- Body weight and blood volume: Larger donors tolerate higher processing volumes, enabling greater platelet collection.
When to Choose Apheresis Platelets Over Pooled Products
Guidelines from the AABB and British Society for Haematology recommend single-donor apheresis platelets in these situations:
- Patients expected to require multiple transfusions (to limit alloimmunization)
- HLA-refractory patients needing matched products
- CMV-seronegative recipients (apheresis products are easier to source from CMV-negative donors)
- Neonates and pediatric patients
- When pathogen-reduced products are mandated by institutional policy
Frequently Asked Questions
How long do apheresis platelets last after collection?
Standard shelf life is 5 days when stored at 20–24°C with continuous agitation. Pathogen-reduced products also get 5 days. Cold-stored platelets may eventually extend this, but regulatory approval varies by country.
Are apheresis platelets safer than pooled platelets?
Yes, primarily because they involve exposure to only one donor instead of 4–6. This translates to lower rates of transfusion-transmitted infections, febrile reactions, and HLA alloimmunization. The trade-off is modestly higher cost.
What platelet count triggers a transfusion?
For most stable, non-bleeding patients with bone marrow failure, the threshold is <10 × 10⁹/L. This rises to <20 × 10⁹/L with fever or coagulopathy, <50 × 10⁹/L before invasive procedures, and <100 × 10⁹/L before neurosurgery or ocular surgery.
Can you donate platelets by apheresis if you take aspirin?
No — most blood centers require at least a 48-hour aspirin-free interval (some require 5 days) because aspirin irreversibly inhibits platelet cyclooxygenase, rendering the collected platelets functionally impaired.
What is platelet refractoriness, and how does apheresis help?
Refractoriness means repeated platelet transfusions fail to raise the patient’s count adequately. When caused by HLA antibodies (about 20–30% of refractory cases), HLA-matched apheresis platelets from typed donors are the most effective solution.
Key Takeaways
- Platelet pheresis yields a full therapeutic dose from a single donor, reducing infection and alloimmunization risk compared to pooled products.
- Pathogen reduction technology has become a game-changer — cutting septic reactions by ~75% and potentially eliminating the need for bacterial culture testing.
- Cold-stored platelets and synthetic platelet mimetics represent the next frontier, though widespread clinical adoption is still years away.
- Transfusion thresholds matter: prophylactic transfusion at <10 × 10⁹/L is standard, but clinical context (bleeding, procedures, fever) shifts that number significantly.
- If you’re a patient receiving repeated platelet transfusions and your counts aren’t responding, ask your hematologist about HLA-matched apheresis platelets — they could make the difference.
